Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000155) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
DART Obrindatamab
|
|||||
| Synonyms |
Orlotamab; MGD 009; MGD009
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Phase I; Discontinued | |||||
| SBP Sequence |
>VH1 Chain
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYY ADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTV SS >VL1 Chain DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK >VH2 Chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYAT YYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTL VTVSS >VL2 Chain QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWT PARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL |
|||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS028 | [1] | ||||
| Scaffold Name | DART | |||||
| Scaffold Class | Antibody fragment | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Binder | B7-H3-positive tumors | N.A. | MacroGenics | [1] | |
| CD276 antigen | Binder | B7-H3-positive tumors | N.A. | MacroGenics | [1] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT02628535 | Click to show the Detail | |||||
| Indication | Unresectable or Metastatic B7-H3-Expressing Neoplasms | |||||
| Phase | Phase I | |||||
| Title | Phase I, First-in-Human, Open Label, Dose Escalation Study of?MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms | |||||
| Status | Terminated (Business Decision) | |||||
| Sponsor | MacroGenics | |||||
| NCT03406949 | Click to show the Detail | |||||
| Indication | Relapsed or Refractory B7-H3-Expressing Tumor | |||||
| Phase | Phase I | |||||
| Title | A Phase I, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART? Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors | |||||
| Status | . | |||||
| Sponsor | MacroGenics | |||||